Bromazepam

Bromazepam potentiates existing respiratory insufficiency by enhancing GABAergic inhibition of central respiratory drive. Contraindicated in patients with pre-existing severe respiratory compromise.

GABA-A potentiation relaxes pharyngeal musculature and suppresses the arousal response to obstructive episodes, exacerbating both obstructive and central sleep apnea.

Benzodiazepine-mediated enhancement of central and spinal GABAergic inhibition exacerbates the neuromuscular transmission deficit in myasthenia gravis, risking respiratory muscle failure.

Benzodiazepines produce reinforcement through disinhibition of VTA dopaminergic neurons and through negative reinforcement (relief of anxiety). Patients with substance use disorder history have elevated risk of compulsive use, dose escalation, and dependence.

Bromazepam undergoes hepatic microsomal oxidation (Ochs et al. 1987). Hepatic impairment is expected to reduce clearance and increase both peak concentration and duration of effect. No specific bromazepam hepatic impairment PK study exists — recommendation based on metabolic pathway.

Benzodiazepines as a class carry teratogenicity concerns, particularly cleft palate risk, based on epidemiological associations. No bromazepam-specific human teratogenicity data exist. Use in first trimester only if benefit clearly outweighs risk.

Ochs et al. (1987) demonstrated that elderly subjects have significantly higher peak concentrations, reduced volume of distribution, approximately 50% lower clearance, and increased free fraction compared to young adults. Dose reduction of approximately 50% is recommended.

Patients with known hypersensitivity to bromazepam or any benzodiazepine should not receive the compound due to risk of allergic or idiosyncratic reactions.

All identified fatal bromazepam cases involved polydrug combinations with CNS depressants (alcohol, opioids, antipsychotics, sedating antidepressants). Co-administration produces additive-to-synergistic respiratory depression. FDA boxed warning applies for concomitant benzodiazepine-opioid use.